Project Grant HT94252310139

The National Cancer Institute awarded a $571,271 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston. The goal of this 5-year research project is to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer, an aggressive form of the disease with limited treatment options. The project will explore using a small molecule drug conjugate that targets the prostate-specific membrane...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

The federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,967,999.00 in funding to The Regents of the University of California, San Francisco (UCSF) to develop a CD46 targeted antibody fragment radiopharmaceutical therapy for the treatment of prostate cancer. The award period runs from July 1, 2025 through June 30, 2028. This research aims to advance innovative medical solutions to address critical...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $736,168 to the Sloan-Kettering Institute for Cancer Research to develop first-in-class antibody-drug conjugates (ADCs) and payloads specifically designed for combination with external beam radiotherapy. The key products and services to be delivered include: Developing HER2-directed ADCs containing DNA damage response inhibitors as payloads, which have demonstrated efficacy in vitro and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $404,972 to the University of California, Los Angeles (UCLA) to conduct research on overcoming radiopharmaceutical therapy resistance in prostate cancer. The key focus is to investigate how the enzyme ENPP1 impacts the effectiveness of PSMA-targeting radiopharmaceutical therapy (RPT) by regulating immune signaling pathways in the tumor microenvironment. The research aims to define...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $353,009 to Paramita Therapeutics Inc. to develop "Novel Multivalent PSMA-Targeted Taxane-Conjugates for Bone Metastases in Prostate Cancer." The project aims to synthesize and evaluate PSMA-targeted drug conjugates containing multiple copies of the taxane chemotherapies docetaxel or paclitaxel. The goal is to improve water solubility and selective targeting of prostate cancer...

This federal Project Grant award of $684,107 from the National Cancer Institute (NCI), part of the Department of Health and Human Services, supports research to integrate circulating tumor cell (CTC) and nuclear imaging biomarkers to assess Lutetium-177 PSMA (Lu-PSMA) radiopharmaceutical therapy response and resistance in advanced prostate cancer patients. The research, conducted by The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to develop novel...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research on targeted radioimmunotherapy for glioblastoma, a highly aggressive form of brain cancer. The $432,134 award was granted on June 5, 2025 to the University of Texas MD Anderson Cancer Center. The research aims to develop an innovative treatment approach using IL13RA2, a cell surface receptor expressed on glioblastoma tumors, as a target for delivering cytotoxic radioisotopes....

This Project Grant award of $153,959.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a bispecific fusion protein, APD1-4-1BBL, designed to enhance the safety and efficacy of cancer immunotherapy treatments. The fusion protein is engineered to disrupt the PD-1/PD-L1 interaction while harnessing PD-1 binding to induce localized 4-1BB hyperclustering, which is expected to activate potent antitumor immunity. The award recipient, Auburn...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,283,068 to The Washington University to develop and evaluate next-generation radioimmunotherapies for treating non-Hodgkin lymphoma (NHL). The project aims to advance precision radiopharmaceutical therapies using single-agent and combined beta-particle (Lu-177) and alpha-particle (Ac-225) labeled ofatumumab in preclinical NHL models. This work builds on the institution's prior...